Keri Schaubert was quoted in Law360 discussing how technology companies and generic-drug makers have said the policy, known as the NHK-Fintiv rule after the PTAB rulings that established it, unfairly restricts the ability to seek inter partes review of patents under the America Invents Act. The appeals court "basically closed the door to appealing a denial of an institution of an IPR on the basis of the Fintiv rule," said Keri.

To read more of this article, click here.